Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients
- PMID: 28267530
- DOI: 10.1016/j.ejrad.2016.12.019
Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients
Abstract
Objectives: To investigate the diagnostic value of different MR sequences and 18F-FDG PET data for whole-body restaging of breast cancer patients utilizing PET/MRI.
Methods: A total of 36 patients with suspected tumor recurrence of breast cancer based on clinical follow-up or abnormal findings in follow-up examinations (e.g. CT, MRI) were prospectively enrolled in this study. All patients underwent a PET/CT and subsequently an additional PET/MR scan. Two readers were instructed to identify the occurrence of a tumor relapse in subsequent MR and PET/MR readings, utilizing different MR sequence constellations for each session. The diagnostic confidence for the determination of a malignant or benign lesion was qualitatively rated (3-point ordinal scale) for each lesion in the different reading sessions and the lesion conspicuity (4-point ordinal scale) for the three different MR sequences was additionally evaluated.
Results: Tumor recurrence was present in 25/36 (69%) patients. All three PET/MRI readings showed a significantly higher accuracy as well as higher confidence levels for the detection of recurrent breast cancer lesions when compared to MRI alone (p<0.05). Furthermore, all three PET/MR sequence constellations showed comparable diagnostic accuracy for the identification of a breast cancer recurrence (p>0.05), yet the highest confidence levels were obtained, when all three MR sequences were used for image interpretation. Moreover, contrast-enhanced T1-weighted VIBE imaging showed significantly higher values for the delineation of malignant and benign lesions when compared to T2w HASTE and diffusion-weighted imaging.
Conclusion: Integrated PET/MRI provides superior restaging of breast cancer patients over MRI alone. Facing the need for appropriate and efficient whole-body PET/MR protocols, our results show the feasibility of fast and morphologically adequate PET/MR protocols. However, considering an equivalent accuracy for the detection of breast cancer recurrences in the three PET/MR readings, the application of contrast-agent and the inclusion of DWI in the study protocol seems to be debatable.
Keywords: 18F-FDG; Breast cancer; PET/MRI; Protocol optimization; Whole-body restaging.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.J Nucl Med. 2014 Feb;55(2):191-7. doi: 10.2967/jnumed.113.123646. Epub 2013 Dec 5. J Nucl Med. 2014. PMID: 24309383
-
Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.PLoS One. 2017 Feb 22;12(2):e0172553. doi: 10.1371/journal.pone.0172553. eCollection 2017. PLoS One. 2017. PMID: 28225831 Free PMC article.
-
Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies.J Nucl Med. 2014 Dec;55(12):1930-5. doi: 10.2967/jnumed.114.146886. Epub 2014 Nov 13. J Nucl Med. 2014. PMID: 25453042
-
PET/MRI of the breast.Eur J Radiol. 2017 Sep;94:A26-A34. doi: 10.1016/j.ejrad.2017.05.006. Epub 2017 May 10. Eur J Radiol. 2017. PMID: 28549570 Review.
-
Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.Eur J Radiol. 2018 Oct;107:158-165. doi: 10.1016/j.ejrad.2018.09.003. Epub 2018 Sep 5. Eur J Radiol. 2018. PMID: 30292261
Cited by
-
Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.PLoS One. 2021 Dec 2;16(12):e0260804. doi: 10.1371/journal.pone.0260804. eCollection 2021. PLoS One. 2021. PMID: 34855886 Free PMC article.
-
Clinical advances in PET-MRI for breast cancer.Lancet Oncol. 2022 Jan;23(1):e32-e43. doi: 10.1016/S1470-2045(21)00577-5. Lancet Oncol. 2022. PMID: 34973230 Free PMC article. Review.
-
What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?Eur Radiol. 2019 Apr;29(4):1787-1798. doi: 10.1007/s00330-018-5720-8. Epub 2018 Sep 28. Eur Radiol. 2019. PMID: 30267154
-
Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study.Cancers (Basel). 2019 Sep 26;11(10):1444. doi: 10.3390/cancers11101444. Cancers (Basel). 2019. PMID: 31561604 Free PMC article.
-
Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in breast cancer recurrence: a systematic review and meta-analysis.Front Med (Lausanne). 2025 Aug 1;12:1602415. doi: 10.3389/fmed.2025.1602415. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40823564 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical